Search
Dalfopristin
go.drugbank.com/drugs/DB01764ApprovedDalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalMBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal
Bacampicillin
go.drugbank.com/drugs/DB01602ApprovedWithdrawnDuring absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable. … [L39544] It was fully approved by the FDA on May 25, 2023.
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnIt is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation.
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).